CN Bio launches all-in-one organ-on-a-chip system, PhysioMimix Core

CN Bio has announced the launch of PhysioMimix^® Core. Combining the capabilities of CN Bio’s existing suite of instruments, PhysioMimix Core is the first organ-on-a-chip system (OOC) solution to deliver validated performance across single-organ, multi-organ, and higher-throughput configurations within one microphysiological system (MPS).

The PhysioMimix Core provides a universal end-to-end solution for recreating complex human physiology in vitro. Optimized for simplicity and functionality, it offers researchers an all-in-one platform to easily adopt, adapt, and scale OOC workflows as experiments evolve – supporting high throughput screens of up to 288 samples simultaneously.

The System’s benchtop design retains unique tubeless, microfluidic engineering to reduce contamination risk and the need for daily maintenance. Recirculating media and adjustable inter/intra-organ flow rates help maintain biomarker levels and enable long-term studies like repeat dosing or chronic disease modelling. Configured to maximize data output and translatability, the System yields ample material recovery for multi-omics analysis.

Dr Paul Brooks, CEO, CN Bio, commented, “2025 has been an exciting year for the OOC sector, with legislative changes demonstrating a distinct shift towards new approach methodologies (NAMs) and allowing drug developers the flexibility to choose the most effective tools to advance their research,”

“PhysioMimix Core directly addresses the gap in the market for a unified OOC system that is adaptable across the entire drug discovery and development pipeline. We work closely with regulators to anticipate the direction of the field, and this launch represents our focus on streamlining adoption and ensuring our customers stay ahead of that curve.,” he added.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>